Post by Alamar Biosciences, Inc.

Day 2 at #AAIC26 put a spotlight on the growing role of blood-based biomarkers and proteomics in Alzheimer's disease research. Across sessions and posters, researchers shared new insights into disease biology, therapeutic monitoring, and the potential of multi-protein signatures to provide a more complete understanding of neurodegeneration. We're seeing the field move beyond individual biomarkers toward broader biological profiling that captures the complexity of Alzheimer's disease and related dementias. It has been especially exciting to see the breadth of research powered by NULISA™, with more than 140 presentations across AAIC highlighting how highly multiplexed proteomics can help unlock new biological insights. Thank you to everyone who stopped by Booth 530 today to discuss your research and share perspectives on where the field is headed. The momentum around blood-based biomarker discovery has never been stronger. Don't forget to join our Product Theater tomorrow, July 14, 1:20-2:00pm with Dr. Thomas Karikari and Dr. Steve Williams as they discuss "Beyond p‑tau217: Expanding Alzheimer’s Insights with Multiplex Protein Profiling." Looking forward to another great day tomorrow. #AAIC26 #Alzheimers #DementiaResearch #Proteomics #Biomarkers #NULISA

Video Content